Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation

Search Page

Filters

My NCBI Filters

Text availability

Article attribute

Article type

Publication date

Search Results

79 results

Filters applied: . Clear all
Results are displayed in a computed author sort order. The Results By Year timeline is not available.
Page 1
A prospective study on tumour response assessment methods after neoadjuvant endocrine therapy in early oestrogen receptor-positive breast cancer.
López-Velazco JI, Manzano S, Otaño M, Elorriaga K, Bultó N, Herrero J, Lahuerta A, Segur V, Álvarez-López I, Caffarel MM, Urruticoechea A. López-Velazco JI, et al. Among authors: urruticoechea a. Breast Cancer Res. 2024 Jan 3;26(1):3. doi: 10.1186/s13058-023-01756-8. Breast Cancer Res. 2024. PMID: 38173005 Free PMC article.
Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment.
Araujo AM, Abaurrea A, Azcoaga P, López-Velazco JI, Manzano S, Rodriguez J, Rezola R, Egia-Mendikute L, Valdés-Mora F, Flores JM, Jenkins L, Pulido L, Osorio-Querejeta I, Fernández-Nogueira P, Ferrari N, Viera C, Martín-Martín N, Tzankov A, Eppenberger-Castori S, Alvarez-Lopez I, Urruticoechea A, Bragado P, Coleman N, Palazón A, Carracedo A, Gallego-Ortega D, Calvo F, Isacke CM, Caffarel MM, Lawrie CH. Araujo AM, et al. Among authors: urruticoechea a. J Clin Invest. 2022 Apr 1;132(7):e148667. doi: 10.1172/JCI148667. J Clin Invest. 2022. PMID: 35192545 Free PMC article.
Spatial intratumoural heterogeneity in the expression of GIT1 is associated with poor prognostic outcome in oestrogen receptor positive breast cancer patients with synchronous lymph node metastases.
Goicoechea I, Rezola R, Arestin M, M Caffarel M, Cortazar AR, Manterola L, Fernandez-Mercado M, Armesto M, Sole C, Larrea E, M Araujo A, Ancizar N, Plazaola A, Urruticoechea A, Carracedo A, Ruiz I, Alvarez Lopez I, H Lawrie C. Goicoechea I, et al. Among authors: urruticoechea a. F1000Res. 2017 Aug 30;6:1606. doi: 10.12688/f1000research.12393.2. eCollection 2017. F1000Res. 2017. PMID: 29862012 Free PMC article.
Stromal oncostatin M cytokine promotes breast cancer progression by reprogramming the tumor microenvironment.
Araujo AM, Abaurrea A, Azcoaga P, López-Velazco JI, Manzano S, Rodriguez J, Rezola R, Egia-Mendikute L, Valdés-Mora F, Flores JM, Jenkins L, Pulido L, Osorio-Querejeta I, Fernández-Nogueira P, Ferrari N, Viera C, Martín-Martín N, Tzankov A, Eppenberger-Castori S, Alvarez-Lopez I, Urruticoechea A, Bragado P, Coleman N, Palazón A, Carracedo A, Gallego-Ortega D, Calvo F, Isacke CM, Caffarel MM, Lawrie CH. Araujo AM, et al. Among authors: urruticoechea a. J Clin Invest. 2022 Oct 3;132(19):e165107. doi: 10.1172/JCI165107. J Clin Invest. 2022. PMID: 36169029 Free PMC article. No abstract available.
VAV3 mediates resistance to breast cancer endocrine therapy.
Aguilar H, Urruticoechea A, Halonen P, Kiyotani K, Mushiroda T, Barril X, Serra-Musach J, Islam A, Caizzi L, Di Croce L, Nevedomskaya E, Zwart W, Bostner J, Karlsson E, Pérez Tenorio G, Fornander T, Sgroi DC, Garcia-Mata R, Jansen MP, García N, Bonifaci N, Climent F, Soler MT, Rodríguez-Vida A, Gil M, Brunet J, Martrat G, Gómez-Baldó L, Extremera AI, Figueras A, Balart J, Clarke R, Burnstein KL, Carlson KE, Katzenellenbogen JA, Vizoso M, Esteller M, Villanueva A, Rodríguez-Peña AB, Bustelo XR, Nakamura Y, Zembutsu H, Stål O, Beijersbergen RL, Pujana MA. Aguilar H, et al. Among authors: urruticoechea a. Breast Cancer Res. 2014 May 28;16(3):R53. doi: 10.1186/bcr3664. Breast Cancer Res. 2014. PMID: 24886537 Free PMC article.
Molecular response to aromatase inhibitor treatment in primary breast cancer.
Mackay A, Urruticoechea A, Dixon JM, Dexter T, Fenwick K, Ashworth A, Drury S, Larionov A, Young O, White S, Miller WR, Evans DB, Dowsett M. Mackay A, et al. Among authors: urruticoechea a. Breast Cancer Res. 2007;9(3):R37. doi: 10.1186/bcr1732. Breast Cancer Res. 2007. PMID: 17555561 Free PMC article. Clinical Trial.
Phase II study of buparlisib (BKM120) and trastuzumab in patients with HER2+ locally advanced or metastatic breast cancer resistant to trastuzumab-based therapy.
Pistilli B, Pluard T, Urruticoechea A, Farci D, Kong A, Bachelot T, Chan S, Han HS, Jerusalem G, Urban P, Robinson D, Mouhaër SL, Tomaso ED, Massacesi C, Saura C. Pistilli B, et al. Among authors: urruticoechea a. Breast Cancer Res Treat. 2018 Apr;168(2):357-364. doi: 10.1007/s10549-017-4596-7. Epub 2017 Dec 2. Breast Cancer Res Treat. 2018. PMID: 29198055 Free PMC article. Clinical Trial.
Evaluating the clinical effectiveness and safety of various HER2-targeted regimens after prior taxane/trastuzumab in patients with previously treated, unresectable, or metastatic HER2-positive breast cancer: a systematic review and network meta-analysis.
Paracha N, Reyes A, Diéras V, Krop I, Pivot X, Urruticoechea A. Paracha N, et al. Among authors: urruticoechea a. Breast Cancer Res Treat. 2020 Apr;180(3):597-609. doi: 10.1007/s10549-020-05577-7. Epub 2020 Feb 25. Breast Cancer Res Treat. 2020. PMID: 32100144 Free PMC article.
Efficacy and safety of concurrent trastuzumab plus weekly paclitaxel-FEC as primary therapy for HER2-positive breast cancer in everyday clinical practice.
Pernas S, Gil-Gil M, de Olza MO, Gumà A, Climent F, Petit A, Pla MJ, García-Tejedor A, López-Ojeda A, Falo C, Fernandez-Otega A, Mesia C, Pérez-Martin FJ, Urruticoechea A, Germà JR. Pernas S, et al. Among authors: urruticoechea a. Breast Cancer Res Treat. 2012 Aug;134(3):1161-8. doi: 10.1007/s10549-012-2149-7. Epub 2012 Jul 8. Breast Cancer Res Treat. 2012. PMID: 22772380 Clinical Trial.
Efficacy and safety of dasatinib with trastuzumab and paclitaxel in first line HER2-positive metastatic breast cancer: results from the phase II GEICAM/2010-04 study.
Ocana A, Gil-Martin M, Antolín S, Atienza M, Montaño Á, Ribelles N, Urruticoechea A, Falcón A, Pernas S, Orlando J, Montero JC, Escudero MJ, Benito S, Caballero R, Carrasco E, Rojo F, Pandiella A, Ruiz-Borrego M. Ocana A, et al. Among authors: urruticoechea a. Breast Cancer Res Treat. 2019 Apr;174(3):693-701. doi: 10.1007/s10549-018-05100-z. Epub 2019 Jan 3. Breast Cancer Res Treat. 2019. PMID: 30607629 Clinical Trial.
79 results